Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms R13I |
Target |
Action degraders |
Mechanism BTK degraders(Tyrosine-protein kinase BTK degraders) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC71H84Cl2N14O9 |
InChIKeyGNGQHZNNUNCGOZ-KBVIKDRVSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Preclinical | China | 06 Jun 2018 |